A Phase 1b Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors

Trial Profile

A Phase 1b Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs ADXS 31164 (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Oesophageal cancer; Osteosarcoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Advaxis
  • Most Recent Events

    • 13 Apr 2016 Status changed from active, no longer recruiting to recruiting.
    • 18 Feb 2016 Planned primary completion date changed from 1 May 2018 to 1 Aug 2018, according to ClinicalTrials.gov record.
    • 18 Feb 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top